Article
A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.
Molecular medicine reports - 1 Jun 2017
Pamungkas Aryo D, Medriano Carl A, Sim Eunjung, Lee Sungyong, Park Youngja H
Abstract excerpt
The most common type of lung cancer is non‑small cell lung cancer (NSCLC), which is frequently characterized by a mutation in the epidermal growth factor receptor (EGFR). Determining the presence of an EGFR mutation in lung cancer is important, as it determines the type of treatment that a patients will receive. Therefore, the aim of the present study was to apply high‑resolution metabolomics (HRM) using liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.